advertisement

---

1 General aspects (0)   1.1 Epidemiology (6)   1.2 Population genetics (0)   1.3 Pathogenesis (1)   1.4 Quality of life (11)   1.5 Glaucomas as cause of blindness (4)   1.6 Prevention and screening (4) 2 Anatomical structures in glaucoma (0)   2.1 Conjunctiva (3)   2.2 Cornea (10)   2.3 Sclera (4)   2.4 Anterior chamber angle (6)   2.5 Meshwork (0)     2.5.1 Trabecular meshwork (7)     2.5.2 Schlemms canal (2)     2.5.3 Scleral outlet channels (1)   2.6 Aqueous humor dynamics (0)     2.6.1 Production (0)     2.6.2 Outflow (0)       2.6.2.1 Trabecular meshwork (0)       2.6.2.2 Uveoscleral (0)     2.6.3 Compostion (6)   2.7 Episcleral veins and venous pressure (0)   2.8 Iris (6)   2.9 Ciliary body (1)   2.10 Lens (0)   2.11 Vitreous body (0)   2.12 Choroid, peripapillary choroid, peripapillary atrophy (9)   2.13 Retina and retinal nerve fibre layer (29)   2.14 Optic disc (21)   2.15 Optic nerve (0)   2.16 Chiasma and retrochiasmal central nervous system (3)   2.17 Stem cells (0)   2.20 Other (0) 3 Laboratory methods (0)   3.1 Microscopy (3)   3.2 Electron microscopy (1)   3.3 Immunohistochemistry (4)   3.4 Molecular genetics (0)     3.4.1 Linkage studies (0)     3.4.2 Gene studies (13)   3.5 Molecular biology incl. SiRNA (15)   3.6 Cellular biology (29)   3.7 Biochemistry (4)   3.8 Pharmacology (16)   3.9 Pathophysiology (6)   3.10 Immunobiology (8)   3.11 Pharmacogenetics (0)   3.12 Proteomics (2)   3.13 In vivo imaging (0)     3.13.1 Laser Scanning (0)       3.13.1.1 Confocal Scanning Laser Ophthalmoscopy (0)       3.13.1.2 Confocal Scanning Laser Polarimetry (0)     3.13.2 Optical Coherence Tomography (0)       3.13.2.1 Anterior Segment (0)       3.13.2.2 Posterior Segment (0)     3.13.3 RGC Imaging (0)     3.13.4 Other (1)   3.20 Other (0) 4 Tissue culture of ocular cells (0) 5 Experimental glaucoma; animal models (3)   5.1 Rodent (18)   5.2 Primates (3)   5.3 Other (5) 6 Clinical examination methods (0)   6.1 Intraocular pressure measurement; factors affecting IOP (0)     6.1.1 Devices, techniques (2)     6.1.2 Fluctuation, circadian rhythms (4)     6.1.3 Factors affecting IOP (19)   6.2 Tonography, aqueous flow measurement (see also 2.6) (0)   6.3 Biomicroscopy (slitlamp) (0)     6.3.1 Anterior segment (2)     6.3.2 Posterior segment (0)   6.4 Gonioscopy (2)   6.5 Ophthalmoscopy (0)   6.6 Visual field examination and other visual function tests (0)     6.6.1 Conventional manual (0)     6.6.2 Automated (15)     6.6.3 Special methods (e.g. color, contrast, SWAP etc.) (4)   6.7 Electro-ophthalmodiagnosis (1)   6.8 Photography (0)     6.8.1 Anterior segment (1)     6.8.2 Posterior segment (3)   6.9 Computerized image analysis (0)     6.9.1 Laser scanning (0)       6.9.1.1 Confocal Scanning Laser Ophthalmoscopy (3)       6.9.1.2 Confocal Scanning Laser Polarimetry (0)     6.9.2 Optical coherence tomography (0)       6.9.2.1 Anterior (6)       6.9.2.2 Posterior (39)     6.9.5 Other (8)   6.10 Fluorescein (ICG) angiography (0)     6.10.1 Anterior segment (0)     6.10.2 Posterior segment (0)   6.11 Bloodflow measurements (22)   6.12 Ultrasonography and ultrasound biomicroscopy (2)   6.13 Provocative tests (3)   6.19 Telemedicine (0)   6.20 Progression (5)   6.30 Other (9) 8 Refractive errors in relation to glaucoma (0)   8.1 Myopia (3)   8.2 Hypermetropia (0)   8.3 Contact lenses (0)   8.4 Refractive surgical procedures (0)   8.5 Other (0) 9 Clinical forms of glaucomas (0)   9.1 Developmental glaucomas (0)     9.1.1 Congenital glaucoma, Buphthalmos (8)     9.1.2 Juvenile glaucoma (11)     9.1.3 Syndromes of Axenfeld, Rieger, Peters, aniridia (2)     9.1.4 Other (0)   9.2 Primary open angle glaucomas (0)     9.2.1 Ocular hypertension (7)     9.2.2 Other risk factors for glaucoma (2)     9.2.3 Open angle glaucoma with elevated IOP (1)     9.2.4 Normal pressure glaucoma (5)   9.3 Primary angle closure glaucomas (0)     9.3.1 Acute primary angle closure glaucoma (pupillary block) (4)     9.3.2 Chronic primary angle closure glaucoma (pupillary block) (1)     9.3.3 Plateau iris syndrome (1)     9.3.4 Primary angle closure suspect (0)     9.3.5 Primary angle closure (5)     9.3.10 Other (0)   9.4 Glaucomas associated with other ocular and systemic disorders (0)     9.4.1 Steroid-induced glaucoma (4)     9.4.2 Glaucomas associated with disorders of the cornea, conjunctiva, sclera (0)       9.4.2.1 Iridocorneal endothelial syndrome (ICE, incl. irisatrophy) (0)       9.4.2.2 Posterior polymorphous dystrophy (0)       9.4.2.3 Fuchs' endothelial dystrophy (0)       9.4.2.5 Other (0)     9.4.3 Glaucomas associated with disorders of the iris and ciliary body (0)       9.4.3.1 Pigmentary glaucoma (1)       9.4.3.5 Other (0)     9.4.4 Glaucomas associated with disorders of the lens (0)       9.4.4.1 Exfoliation syndrome (25)       9.4.4.2 Glaucomas associated with cataracts (1)       9.4.4.3 Glaucomas associated with lens dislocation (0)       9.4.4.5 Other (1)     9.4.5 Glaucomas associated with disorders of the retina, choroid and vitreous (0)       9.4.5.1 Neovascular glaucoma (2)       9.4.5.5 Other (2)     9.4.6 Glaucomas associated with inflammation, uveitis (8)     9.4.7 Glaucomas associated with ocular trauma (1)     9.4.8 Glaucomas associated with intraocular tumors (2)     9.4.9 Glaucomas associated with elevated episcleral venous pressure (0)       9.4.10 Glaucomas associated with hemorrhage (4)     9.4.11 Glaucomas following intraocular surgery (0)       9.4.11.1 Ciliary block (malignant) glaucoma (2)       9.4.11.2 Glaucomas in aphakia and pseudophakia (8)       9.4.11.3 Epithelial, fibrous, and endothelial proliferation (0)       9.4.11.4 Glaucomas associated with corneal surgery (1)       9.4.11.5 Glaucomas associated with vitreoretinal surgery (5)     9.4.15 Glaucoma in relation to systemic disease (30)     9.4.20 Other (2) 10 Differential diagnosis e.g. anterior and posterior ischemic optic neuropathy (4) 11 Medical treatment (0)   11.1 General management, indication (5)   11.2 Cholinergic drugs (0)   11.3 Adrenergic drugs (0)     11.3.1 Epinephrine (0)     11.3.2 Thymoxamine, dapiprazole (0)     11.3.3 Apraclonidine, brimonidine (2)     11.3.4 Betablocker (0)     11.3.5 Other (0)   11.4 Prostaglandins (9)   11.5 Carbonic anhydrase inhibitors (0)     11.5.1 Systemic (0)     11.5.2 Topical (0)   11.6 Osmotic treatment (0)   11.7 Treatment of bloodflow (0)   11.8 Neuroprotection (17)   11.9 Gene therapy (0)   11.13 Combination therapy (0)     11.13.1 Betablocker and pilocarpine (0)     11.13.2 Betablocker and carbon anhydrase inhibitor (0)     11.13.3 Betablocker and brimonidine (0)     11.13.4 Betablocker and prostaglandin (2)     11.13.5 Other (0)   11.14 Investigational drugs; pharmacological experiments (8)   11.15 Other drugs in relation to glaucoma (11)   11.16 Vehicles, delivery systems, pharmacokinetics, formulation (9)   11.17 Cooperation with medical therapy e.g. persistency, compliance, adherence (4)   11.20 Other (4) 12 Surgical treatment (0)   12.1 General management, indication (4)   12.2 Laser iridotomy (0)   12.3 Laser iridoplasty (1)   12.4 Laser trabeculoplasty and other laser treatment of the angle (2)   12.7 Surgical iridectomy (0)   12.8 Filtering surgery (0)     12.8.1 Without tube implant (15)     12.8.2 With tube implant or other drainage devices (19)     12.8.3 Non-perforating (3)     12.8.4 Using laser (0)     12.8.5 Other (0)     12.8.10 Woundhealing antifibrosis (10)     12.8.11 Complications, endophthalmitis (8)   12.9 Trabeculotomy, goniotomy (8)   12.10 Cyclodestruction (2)   12.11 Cyclodialysis (1)   12.12 Cataract extraction (0)     12.12.1 Intracapsular (0)     12.12.2 Extracapsular (0)     12.12.3 Phacoemulsification (5)   12.14 Combined cataract extraction and glaucoma surgery (0)     12.14.1 Intracapsular (0)     12.14.2 Extracapsular (0)     12.14.3 Phacoemulsification (3)   12.15 Capsulotomy (0)   12.16 Vitrectomy (3)   12.17 Anesthesia (0)   12.20 Other (1) 13 Therapeutic prognosis and outcome (0)   13.1 Prognostic factors (0)   13.2 Outcome (0)     13.2.1 IOP (0)     13.2.2 Visual field (0)       13.2.2.1 Progression (0)       13.2.2.2 Improvement (0)     13.2.3 Other (0) 14 Costing studies; pharmacoeconomics (4) 15 Miscellaneous (23)

---

Abstract #78294 Published in IGR 19-4

Effect of ranibizumab on levels of IL-6 and VEGF in peripheral blood and aqueous humor of glaucoma rat model and association of IL-6 and VEGF with optic nerve damage

Song Y; Song Q; Li L; Xu J; Liu X
Experimental and therapeutic medicine 2018; 16: 2506-2510

---

This study aims to investigate the effect of intravitreal injection of ranibizumab on glaucoma rat model and its effect on optic nerve injury. A total of 125 SD rats were used to establish glaucoma models. Of them, 80 well-established model were selected, 40 of which received intravitreal injections of ranibizumab and were assigned to the observation group. The remaining 40 received no drug and were assigned to the control group. After rats were sacrificed at the time-points, the retina was harvested. Numbers of retinal ganglion cells (RGCs) were counted under a fluorescence microscope. In the meantime, levels of interleukin-6 (IL-6) and vascular endothelial growth factor (VEGF) in peripheral blood and aqueous humor were determined. The levels of IL-6 and VEGF in peripheral blood and aqueous humor decreased gradually over the time of treatment in the observation group (P<0.05). In the control group the levels of IL-6 in peripheral blood and aqueous humor increased gradually over time (P<0.05). At the same time-point, the IL-6 level was higher in the control group than that in the observation group (P<0.05). The VEGF level in the observation group was lower in day 21 than that in day 7 (P<0.05). The VEGF level was higher in the control group than that in the observation group (P<0.05). The number of RGCs in the observation group increased gradually over the time of treatment, and there were significant differences in the number of RGCs between day 7 and 14, as well as day 14 and 21 (P<0.05). The number of RGCs in the control group decreased gradually over time (P<0.05). The levels of IL-6 and VEGF were all negatively correlated with the number of RGCs, and the correlation coefficient r and P-value were -0.743 and 0.012, and -0.675 and 0.022, respectively. Ranibizumab attenuated optic nerve injury by reducing levels of IL-6 and VEGF in peripheral blood and aqueous humor of glaucoma rat model.

Department of Ophthalmology, People's Hospital of Dongying, Dongying, Shandong 257091, P.R. China.

Full article

---

Classification:

11.15 Other drugs in relation to glaucoma (Part of: 11 Medical treatment)
5.1 Rodent (Part of: 5 Experimental glaucoma; animal models)

---

• ← Previous
• Next →

---